KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Preferred Shares (2018 - 2021)

Historic Preferred Shares for Xenon Pharmaceuticals (XENE) over the last 6 years, with Q4 2021 value amounting to $7.7 million.

  • Xenon Pharmaceuticals' Preferred Shares changed 0.0% to $7.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $7.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $7.7 million for FY2021, which is 0.0% changed from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Preferred Shares stood at $7.7 million for Q4 2021, which was down 0.0% from $7.7 million recorded in Q3 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' Preferred Shares peaked at $21.8 million during Q1 2018, and registered a low of $7.7 million during Q1 2019.
  • In the last 4 years, Xenon Pharmaceuticals' Preferred Shares had a median value of $7.7 million in 2019 and averaged $9.9 million.
  • In the last 5 years, Xenon Pharmaceuticals' Preferred Shares plummeted by 6457.27% in 2019 and then changed by 0.0% in 2020.
  • Over the past 4 years, Xenon Pharmaceuticals' Preferred Shares (Quarter) stood at $11.9 million in 2018, then tumbled by 35.2% to $7.7 million in 2019, then changed by 0.0% to $7.7 million in 2020, then changed by 0.0% to $7.7 million in 2021.
  • Its Preferred Shares was $7.7 million in Q4 2021, compared to $7.7 million in Q3 2021 and $7.7 million in Q2 2021.